{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:26:22Z","timestamp":1789244782373,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.modpat.2023.100273","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T11:33:43Z","timestamp":1688729623000},"page":"100273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7645-631X","authenticated-orcid":false,"given":"John L.","family":"McAfee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raza S.","family":"Hoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Hoyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana A.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo A.","family":"Koyfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Geiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miglena K.","family":"Komforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.modpat.2023.100273_bib1","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/hed.23350","article-title":"Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database","volume":"36","author":"Jayaprakash","year":"2014","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.modpat.2023.100273_bib2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hed.25035","article-title":"Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: a nationwide case series of 35 patients in The Netherlands","volume":"40","author":"Boon","year":"2018","journal-title":"Head Neck"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib3","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/annonc\/mdx771","article-title":"A\u00a0prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma","volume":"29","author":"Fushimi","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.modpat.2023.100273_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.18.00545","article-title":"Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma","volume":"37","author":"Takahashi","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.modpat.2023.100273_bib5","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1002\/hed.25392","article-title":"Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas","volume":"40","author":"Park","year":"2018","journal-title":"Head Neck"},{"issue":"3","key":"10.1016\/j.modpat.2023.100273_bib6","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/hed.23429","article-title":"Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment","volume":"36","author":"Falchook","year":"2014","journal-title":"Head Neck"},{"key":"10.1016\/j.modpat.2023.100273_bib7","article-title":"The role of the EZH2 and H3K27me3 expression as a predictor of clinical outcomes in salivary duct carcinoma patients: a large-series study with emphasis on the relevance to the combined androgen blockade and HER2-targeted therapy","volume":"11","author":"Saigusa","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.modpat.2023.100273_bib8","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3389\/fonc.2019.00701","article-title":"First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-a retrospective study","volume":"9","author":"Viscuse","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100273_bib9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.modpat.2023.100273_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.693394","article-title":"HER2 positivity in histological subtypes of salivary gland carcinoma: a systematic review and meta-analysis","volume":"11","author":"Egebjerg","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.modpat.2023.100273_bib11","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41379-021-00999-0","article-title":"ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing","volume":"35","author":"Ferguson","year":"2022","journal-title":"Mod Pathol"},{"issue":"20","key":"10.1016\/j.modpat.2023.100273_bib12","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib13","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s12105-020-01163-x","article-title":"Increased ERBB2 gene copy numbers reveal a subset of salivary duct carcinomas with high densities of tumor infiltrating lymphocytes and PD-L1 expression","volume":"14","author":"Chatzopoulos","year":"2020","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.modpat.2023.100273_bib14","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.modpat.2023.100273_bib15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2022.05.019","article-title":"Discerning subsets of breast cancer with very low and absent HER2 protein expression","volume":"127","author":"Boyraz","year":"2022","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100273_bib16","first-page":"1","article-title":"multimode: an R package for mode assessment","volume":"97","author":"Ameijeiras-Alonso","year":"2021","journal-title":"J\u00a0Stat Softw"},{"issue":"1","key":"10.1016\/j.modpat.2023.100273_bib17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1214\/aos\/1176346577","article-title":"The dip test of unimodality","volume":"13","author":"Hartigan","year":"1985","journal-title":"Ann Stat"},{"key":"10.1016\/j.modpat.2023.100273_bib18","author":"Maechler"},{"key":"10.1016\/j.modpat.2023.100273_bib19","author":"Therneau"},{"key":"10.1016\/j.modpat.2023.100273_bib20","author":"Kassambara"},{"issue":"1","key":"10.1016\/j.modpat.2023.100273_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/BF00301495","article-title":"Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma","volume":"192","author":"Kleinsasser","year":"1968","journal-title":"Arch Klin Exp Ohren Nasen Kehlkopfheilkd"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2559.2012.04252.x","article-title":"Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes","volume":"61","author":"Di Palma","year":"2012","journal-title":"Histopathology"},{"issue":"18","key":"10.1016\/j.modpat.2023.100273_bib23","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1158\/1078-0432.CCR-16-0637","article-title":"Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer","volume":"22","author":"Dalin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"35","key":"10.1016\/j.modpat.2023.100273_bib24","doi-asserted-by":"crossref","first-page":"59023","DOI":"10.18632\/oncotarget.19812","article-title":"Biomarker immunoprofile in salivary duct carcinomas: clinicopathological and prognostic implications with evaluation of the revised classification","volume":"8","author":"Takase","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.modpat.2023.100273_bib25","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","article-title":"Molecular patterns in salivary duct carcinoma identify prognostic subgroups","volume":"33","author":"Mueller","year":"2020","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.1365-2559.2003.01598.x","article-title":"Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study","volume":"42","author":"Vincent-Salomon","year":"2003","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.modpat.2023.100273_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jclinpath-2014-202571","article-title":"Updated UK Recommendations for HER2 assessment in breast cancer","volume":"68","author":"Rakha","year":"2015","journal-title":"J\u00a0Clin Pathol"},{"issue":"8","key":"10.1016\/j.modpat.2023.100273_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1288\/00005537-199208000-00013","article-title":"Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness","volume":"102","author":"Sugano","year":"1992","journal-title":"Laryngoscope"},{"issue":"1","key":"10.1016\/j.modpat.2023.100273_bib29","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/0030-4220(94)90120-1","article-title":"Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein","volume":"78","author":"Barnes","year":"1994","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1365-2559.2003.01600.x","article-title":"Expression of HER-2\/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2003","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.modpat.2023.100273_bib31","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/cncr.21116","article-title":"Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases","volume":"103","author":"Jaehne","year":"2005","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.modpat.2023.100273_bib32","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archotol.133.10.1031","article-title":"Amplification and overexpression of HER2\/neu gene and HER2\/neu protein in salivary duct carcinoma of the parotid gland","volume":"133","author":"Cornolti","year":"2007","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"11","key":"10.1016\/j.modpat.2023.100273_bib33","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/PAS.0b013e3180caa099","article-title":"Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients","volume":"31","author":"Williams","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.modpat.2023.100273_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/PAI.0b013e31802e91b2","article-title":"Her-2\/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study","volume":"16","author":"Johnson","year":"2008","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100273_bib35","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.oraloncology.2009.05.635","article-title":"Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs)","volume":"45","author":"Locati","year":"2009","journal-title":"Oral Oncol"},{"issue":"8","key":"10.1016\/j.modpat.2023.100273_bib36","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1158\/1078-0432.CCR-09-0238","article-title":"Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance","volume":"16","author":"Williams","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/bjc.2011.605","article-title":"Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer","volume":"106","author":"Ettl","year":"2012","journal-title":"Br J Cancer"},{"issue":"20","key":"10.1016\/j.modpat.2023.100273_bib38","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/cncr.30179","article-title":"Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations","volume":"122","author":"Chiosea","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.modpat.2023.100273_bib39","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1001\/jamaoto.2015.3930","article-title":"A\u00a020-year review of 75 cases of salivary duct carcinoma","volume":"142","author":"Gilbert","year":"2016","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"Suppl 1","key":"10.1016\/j.modpat.2023.100273_bib40","first-page":"E820","article-title":"Salivary duct carcinoma: treatment, outcomes, and patterns of failure","volume":"38","author":"Johnston","year":"2016","journal-title":"Head Neck"},{"issue":"18","key":"10.1016\/j.modpat.2023.100273_bib41","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1002\/cncr.31600","article-title":"Frequent PTEN loss and differential HER2\/PI3K signaling pathway alterations in salivary duct carcinoma: implications for targeted therapy","volume":"124","author":"Saintigny","year":"2018","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/ijc.31353","article-title":"A\u00a0clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from the Netherlands","volume":"143","author":"Boon","year":"2018","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2023.100273_bib43","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s12105-017-0833-y","article-title":"Expression of hormone receptors and HER-2 in benign and malignant salivary gland tumors","volume":"12","author":"Can","year":"2018","journal-title":"Head Neck Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s12105-018-0984-5","article-title":"Expression of PTEN, androgen receptor, HER2\/neu, cytokeratin 5\/6, estrogen receptor-beta, HMGA2, and PLAG1 in salivary duct carcinoma","volume":"13","author":"Liang","year":"2019","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.modpat.2023.100273_bib45","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2019.03.004","article-title":"The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement","volume":"88","author":"Dogan","year":"2019","journal-title":"Hum Pathol"},{"issue":"17","key":"10.1016\/j.modpat.2023.100273_bib46","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"issue":"11","key":"10.1016\/j.modpat.2023.100273_bib47","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/modpathol.2009.117","article-title":"Delay to formalin fixation effect on breast biomarkers","volume":"22","author":"Khoury","year":"2009","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100273_bib48","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.modpat.2023.100273_bib49","first-page":"1033","article-title":"Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma","volume":"11","author":"Kapadia","year":"1998","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.modpat.2023.100273_bib50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000478-200004000-00014","article-title":"Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature","volume":"24","author":"Fan","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100273_bib51","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cncr.9050","article-title":"Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis","volume":"93","author":"Moriki","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2023.100273_bib52","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1309\/RVTP1G0Q727WJUQD","article-title":"Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors","volume":"119","author":"Nasser","year":"2003","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.modpat.2023.100273_bib53","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/PAS.0000000000000413","article-title":"Salivary duct carcinoma: the predominance of apocrine morphology, prevalence of histologic variants, and androgen receptor expression","volume":"39","author":"Williams","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100273_bib54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.humpath.2019.08.007","article-title":"Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance","volume":"93","author":"Xu","year":"2019","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.modpat.2023.100273_bib55","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1002\/hed.25857","article-title":"Prognostic markers in salivary gland cancer and their impact on survival","volume":"41","author":"Szewczyk","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.modpat.2023.100273_bib56","article-title":"HER2 status in recurrent\/metastatic androgen receptor overexpressing salivary gland carcinoma patients","volume":"12","author":"Cavalieri","year":"2022","journal-title":"Front Oncol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223001783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395223001783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:25:31Z","timestamp":1760232331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395223001783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0893395223001783"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100273","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ERBB2 Amplification and HER2 Expression in Salivary Duct Carcinoma: Evaluation of Scoring Guidelines and Potential for Expanded Anti-HER2 Therapy","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100273","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100273"}}